Logo image of FVE

FIVE STAR SENIOR LIVING INC (FVE) Stock Fundamental Analysis

NASDAQ:FVE - Nasdaq - US33832D1063 - Common Stock

2.94  +0.07 (+2.44%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to FVE. FVE was compared to 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of FVE have multiple concerns. FVE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FVE had negative earnings in the past year.
FVE Yearly Net Income VS EBIT VS OCF VS FCFFVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 50M -50M -100M

1.2 Ratios

Industry RankSector Rank
ROA -4.4%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FVE Yearly ROA, ROE, ROICFVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -20 -40 -60 -80 -100

1.3 Margins

Industry RankSector Rank
OM 0.52%
PM (TTM) -1.57%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FVE Yearly Profit, Operating, Gross MarginsFVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 40 60 80

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, FVE has more shares outstanding
FVE has a worse debt/assets ratio than last year.
FVE Yearly Shares OutstandingFVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M
FVE Yearly Total Debt VS Total AssetsFVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.16 indicates that FVE is not a great score, but indicates only limited risk for bankruptcy at the moment.
FVE has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 2.16
ROIC/WACCN/A
WACCN/A
FVE Yearly LT Debt VS Equity VS FCFFVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 1.51 indicates that FVE should not have too much problems paying its short term obligations.
FVE has a Quick Ratio of 1.51. This is a normal value and indicates that FVE is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.51
FVE Yearly Current Assets VS Current LiabilitesFVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for FVE have decreased strongly by -117.90% in the last year.
FVE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.26%.
Measured over the past years, FVE shows a decrease in Revenue. The Revenue has been decreasing by -3.15% on average per year.
EPS 1Y (TTM)-117.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-283.33%
Revenue 1Y (TTM)-15.26%
Revenue growth 3Y-5.89%
Revenue growth 5Y-3.15%
Sales Q2Q%-23.52%

3.2 Future

FVE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.66% yearly.
The Revenue is expected to decrease by -9.86% on average over the next years.
EPS Next Y-120%
EPS Next 2Y28.06%
EPS Next 3Y53.83%
EPS Next 5Y61.66%
Revenue Next Year-19.45%
Revenue Next 2Y-18%
Revenue Next 3Y-11.55%
Revenue Next 5Y-9.86%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
FVE Yearly Revenue VS EstimatesFVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
FVE Yearly EPS VS EstimatesFVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

FVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FVE Price Earnings VS Forward Price EarningsFVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.27
FVE Per share dataFVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

FVE's earnings are expected to grow with 53.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.06%
EPS Next 3Y53.83%

More info and screens

0

5. Dividend

5.1 Amount

FVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIVE STAR SENIOR LIVING INC

NASDAQ:FVE (1/27/2022, 8:26:29 PM)

2.94

+0.07 (+2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)02-23 2022-02-23
Inst Owners0%
Inst Owner Change0%
Ins Owners0.72%
Ins Owner Change0%
Market Cap93.36M
Analysts80
Price Target6.63 (125.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB N/A
EV/EBITDA 0.27
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS32.74
BVpS6.04
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 0.52%
PM (TTM) -1.57%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover2.81
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.51
Altman-Z 2.16
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-283.33%
EPS Next Y-120%
EPS Next 2Y28.06%
EPS Next 3Y53.83%
EPS Next 5Y61.66%
Revenue 1Y (TTM)-15.26%
Revenue growth 3Y-5.89%
Revenue growth 5Y-3.15%
Sales Q2Q%-23.52%
Revenue Next Year-19.45%
Revenue Next 2Y-18%
Revenue Next 3Y-11.55%
Revenue Next 5Y-9.86%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A